Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05375370
NA

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA

Sponsor: University Hospital, Rouen

View on ClinicalTrials.gov

Summary

The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.

Official title: Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA: a Prospective Cohort Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2022-08-04

Completion Date

2029-02

Last Updated

2026-02-06

Healthy Volunteers

No

Interventions

OTHER

circulating tumor DNA dosage

blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma

Locations (1)

Chu Rouen

Rouen, France